Shorter Androgen Blockade for High-Risk Prostate Cancer Patients Treated with Radiotherapy: Trial Results

Reducing ADT from 36 to 18 months Improves Quality of Life, Does Not Reduce Survival

A randomized Phase III Trial of outcomes for high-risk prostate cancer patients treated with radiotherapy and either 36 or 18 months of androgen deprivation therapy has found “no difference in survival between the two groups, with the 18-month group experiencing a better quality of life.”

Survival and biochemical failure rates between 36 months and 18 months of ADT combined with Radiotherapy for men with high-risk prostate. cancer ).

Continue reading “Shorter Androgen Blockade for High-Risk Prostate Cancer Patients Treated with Radiotherapy: Trial Results”